Tempest Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Tempest Therapeutics

18/03/2024 11:02

* Tempest Therapeutics Inc  TPST.OQ   TPST.O  is expected
to show
no change in quarterly revenue when it reports  results on March
20 (estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Tempest Therapeutics Inc
is
for a loss of 39 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tempest
Therapeutics Inc is $13.00​, above​ its last closing price
of $3.64. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.56       -0.57      -0.48     Beat    16.2
 Jun. 30 2023  -0.55       -0.52      -0.54     Missed  -4.3
 Mar. 31 2023  -0.65       -0.64      -0.55     Beat    14.4​
 Dec. 31 2022              -0.76      -0.63     Beat    17
 ​​Sep.        -0.81       -0.80      -0.66     Beat    17.8
 30 2022                                                
 Jun. 30 2022  -0.93       -0.92      -0.79     Beat    14.4​
 Mar. 31 2022  -1.12       -1.12      -1.18     Missed  -5.7
 Dec. 31 2021              -1.23      -1.12     Beat    9.1
 This summary was machine generated March 18 at 11:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)